Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/30/2024 | $6.00 → $1.00 | Buy → Underperform | BofA Securities |
| 6/27/2024 | $6.00 → $1.00 | Buy → Neutral | H.C. Wainwright |
| 8/28/2023 | $15.00 → $5.00 | Overweight → Neutral | JP Morgan |
| 11/14/2022 | $15.00 → $7.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/11/2022 | $13.00 → $7.00 | Buy → Neutral | Goldman |
| 10/17/2022 | $12.00 | Buy | H.C. Wainwright |
| 1/6/2022 | $25.00 → $20.00 | Overweight | Morgan Stanley |
| 7/12/2021 | $25.00 | Buy | BofA Securities |
SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
BofA Securities downgraded Lyell Immunopharma from Buy to Underperform and set a new price target of $1.00 from $6.00 previously
H.C. Wainwright downgraded Lyell Immunopharma from Buy to Neutral and set a new price target of $1.00 from $6.00 previously
JP Morgan downgraded Lyell Immunopharma from Overweight to Neutral and set a new price target of $5.00 from $15.00 previously
Cash, cash equivalents and marketable securities of $632.7 million as of June 30, 2023 support advancing multiple product candidates through key clinical milestonesRemain on track for initial clinical data from two lead product candidates in 2024Further strengthened executive leadership with appointment of Matt Lang, J.D., as Chief Business Officer SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for the second quarter ended June 30, 2023. "Lyell continues
SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that Matthew Lang, J.D. has joined the executive management team as Chief Business Officer. In this newly created role, Mr. Lang will serve on Lyell's executive committee and will be responsible for Lyell's legal, compliance, human resources, alliance management and early commercialization teams. He will also serve as Lyell's Chief Legal Officer and Corporate Secretary. "Matt is an experienced company builder who has successfully led growth in compl
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Lynn Seely, MD, a member of the company's board and former president and chief executive officer (CEO) of Myovant Sciences, has been named Lyell's president & CEO effective today. Dr. Seely succeeds Ms. Liz Homans following a four-year tenure as president and then CEO. Ms. Homans will remain a consultant to the company through June 2024. Dr. Seely has extensive biopharmaceutical leadership experience with a track record of success building companies
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/refractory B-cell non-Hodgkin's lymphomaPresenting initial data from Phase 1 multi-center clinical trial of IMPT-314 at the American Society of Hematology 2024 (ASH) Annual MeetingPresenting three abstracts at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting highlighting anti-exhaustion technology and product candidates being advanced in Lyell's pipelineCash, cash equivalents and marketable securities of $460.7 million as of September 30, 2024 funds the Company th
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, today announced that an abstract highlighting initial clinical data from the Phase 1-2 study of IMPT-314 in large B-cell lymphoma will be presented by Sarah M. Larson, M.D., Associate Professor, Department of Medicine, Medical Director, Immune Effector Cell Therapy Program, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, at the 66th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, CA, Decem
Acquisition strengthens Lyell's clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate expected to initiate pivotal development in 2025 in patients in the 3rd line setting with B-cell non-Hodgkin lymphoma who have not yet been exposed to CAR T-cell therapySumant Ramachandra, M.D., Ph.D., MBA, appointed to Lyell's Board of Directors SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage T-cell reprogramming company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, announced today that it has completed
B of A Securities analyst Geoff Meacham maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $9 to $6.
HC Wainwright & Co. analyst Mitchell Kapoor downgrades Lyell Immunopharma (NASDAQ:LYEL) from Buy to Neutral and lowers the price target from $6 to $1.
10-Q - Lyell Immunopharma, Inc. (0001806952) (Filer)
8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
3 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
Strengthens Lyell's clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT's multi-center Phase 1-2 clinical trial of IMPT-314 in patients with large B-cell lymphoma treated in the 3rd line CAR-naïve setting to be presented at a major medical conference later this year; initiation of a pivotal trial for IMPT-314 expected in 2025Lyell has prioritized its pipeline to focus on next-generation CAR T-cell therapies, including IMPT-314 and LYL119, and is discontinuing development of LYL797, LYL845 and earlier-stage TIL programsCash runway following the close of the transaction is expected to fund operations into 2027, through impor
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 106 CAR T cells)First demonstration that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumorsNo significant safety signal related to LYL797 observed in patients without lung involvement; treatable pneumonitis observed in patients with lung metastatic disease; dose escalation continues in separate cohortsExpanding development into new tumor types including ROR1+ relapsed/refractory platinum-resistant ovarian cancer, endometrial cancer, multiple